Blom Goldman U, Anderson M, Wennberg B, Lind P
Department of Oncology , Karolinska University Hospital, Stockholm , Sweden ; Department of Oncology-Pathology , Karolinska Institutet , Stockholm , Sweden.
Department of Physiology , Stockholm Söder Hospital , Stockholm , Sweden.
J Radiother Pract. 2014 Jun;13(2):211-217. doi: 10.1017/S1460396913000228. Epub 2013 Jun 7.
We studied symptomatic radiation pneumonitis (RP) and changes in pulmonary function tests (PFTs) after loco-regional radiotherapy (LRRT) with lung constraints in breast cancer (BC).
Sixty-four women underwent PFTs before and 5 months after 3D planned LRRT for BC. The incidentally irradiated ipsilateral lung was minimised to <30%. Patients were monitored for symptoms of RP 1, 4 and 7 months after radiotherapy (RT) and data on covariates were collected prospectively. The outcome was compared with previous treatment series.
Pneumonitis was less frequent with the applied constraint, that is, four mild and one moderate case, than in our previous report ( < 0·001). In multivariate analyses, neither dosimetric data nor covariates appeared to influence mean changes in vital capacity [-0·11L, standard error of the mean (SEM) 0·03] or diffusing capacity of the lung for carbon monoxide (DLCO) (-0·20 mmol/kPa/min, SEM 0·01), except for pre-RT chemotherapy, which diminished the change in DLCO 5 months post-RT.
The used constraint and 3D planning lowered the rate of RP and short-term changes in PFTs compared with our previous treatment series. Pre-RT chemotherapy affects DLCO baseline levels. Rates of side effects should be continuously studied when new target definitions or therapies are introduced in LRRT of BC.
我们研究了在乳腺癌(BC)局部区域放疗(LRRT)时采用肺部限制条件下的症状性放射性肺炎(RP)及肺功能测试(PFTs)的变化。
64名女性在接受针对BC的三维计划LRRT之前及之后5个月进行了PFTs。将偶然受照射的同侧肺体积最小化至<30%。在放疗(RT)后1、4和7个月对患者进行RP症状监测,并前瞻性收集协变量数据。将结果与之前的治疗系列进行比较。
采用该限制条件时,肺炎的发生率较低,即4例轻度和1例中度病例,低于我们之前的报告(<0·001)。在多变量分析中,除了放疗前化疗会减少放疗后5个月一氧化碳弥散量(DLCO)的变化外,剂量学数据和协变量似乎均未影响肺活量的平均变化[-0·11L,平均标准误差(SEM)0·03]或肺一氧化碳弥散量(-0·20 mmol/kPa/min,SEM 0·01)。
与我们之前的治疗系列相比,所采用的限制条件和三维计划降低了RP的发生率及PFTs的短期变化。放疗前化疗会影响DLCO的基线水平。当在BC的LRRT中引入新的靶区定义或治疗方法时,应持续研究副作用的发生率。